Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

PHASE4CompletedINTERVENTIONAL
Enrollment

287

Participants

Timeline

Start Date

April 29, 2022

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2025

Conditions
Asthma
Interventions
DRUG

Tezepelumab

Participants will be receiving subcutaneous injection of tezepelumab.

Trial Locations (37)

10595

Research Site, Valhalla

11423

Research Site, Hollis

14642

Research Site, Rochester

14845

Research Site, Horseheads

16602

Research Site, Altoona

19140

Research Site, Philadelphia

20037

Research Site, Washington D.C.

20772

Research Site, Upper Marlboro

22903

Research Site, Charlottesville

27514

Research Site, Chapel Hill

28401

Research Site, Wilmington

29607

Research Site, Greenville

36608

Research Site, Mobile

37075

Research Site, Hendersonville

40509

Research Site, Lexington

43617

Research Site, Toledo

48109

Research Site, Ann Arbor

48197

Research Site, Ypsilanti

55109

Research Site, Saint Paul

60611

Research Site, Chicago

63110

Research Site, St Louis

68114

Research Site, Omaha

68505

Research Site, Lincoln

70112

Research Site, New Orleans

73120

Research Site, Oklahoma City

75069

Research Site, McKinney

76104

Research Site, Fort Worth

78229

Research Site, San Antonio

80907

Research Site, Colorado Springs

85234

Research Site, Gilbert

90017

Research Site, Los Angeles

90815

Research Site, Long Beach

92270

Research Site, Rancho Mirage

92683

Research Site, Westminster

98664

Research Site, Vancouver

06510

Research Site, New Haven

02886

Research Site, Warwick

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY